A Summer of Hematologic Science 4
Total Page:16
File Type:pdf, Size:1020Kb
September 2009 www.clinicaladvances.com Volume 7, Issue 9, Supplement 15 Faculty Bruce D. Cheson, MD Head of Hematology Lombardi Comprehensive Cancer Center Georgetown University Hospital A Summer of Washington, DC Elizabeth Ashforth, PhD Hematologic Science Principal Chado Healthcare Consulting, LLC Highlights from the 45th Annual Meeting of the American Society of Clinical Oncology, the 14th Congress of the European Hematology Association, and the 2009 Pan Pacific Lymphoma Conference A CME Activity Approved for 1.5 AMA PRA Category 1 Credit(s) TM Release Date: September, 2009 Expiration Date: September 30, 2010 Estimated time to complete activity: 1.5 hour Sponsored by Postgraduate Institute for Medicine Supported through an educational grant from Celgene Corporation and Cephalon Oncology Table of Contents CME Certification Information and Faculty Disclosure 3 A Summer of Hematologic Science 4 Commentary Bruce D. Cheson, MD 19 CME Post-Test 23 CME Evaluation Form 24 Disclaimer Funding for this Presentations Review has been provided through an educational grant from Celegne Corporation and Cephalon Oncology. Support of this monograph does not imply the supporter’s agreement with the views expressed herein. Every effort has been made to ensure that drug usage and other information are presented accurately; however, the ultimate responsibility rests with the prescribing physician. Millennium Medical Publishing, Inc, the supporter, and the participants shall not be held responsible for errors or for any consequences arising from the use of information contained herein. Readers are strongly urged to consult any relevant primary literature. No claims or endorsements are made for any drug or compound at present under clinical investigation. ©2009 Millennium Medical Publishing, Inc. 611 Broadway, Suite 310, New York, NY 10012. Printed in the USA. All rights reserved, including the right of reproduction, in whole or in part, in any form. Target Audience Disclosures: This activity has been designed to meet the educational needs of he- Bruce D. Cheson—Consultant: Celgene Corporation, Cephalon, Roche/ matologist and oncologists involved in the management of patients Genentech, Abbott Labs, Astellas Pharma; Non-CME services: Celgene with lymphoma, leukemia, multiple myeloma, and myelodysplastic Corporation, Cephalon, Millennium Pharmaceuticals syndromes. Elizabeth Ashforth, PhD—No financial relationships to disclose. Statement of Need/Program Overview The following PIM planners and managers, Linda Graham, RN, BSN, Data are emerging on novel agents as well as new combination regi- BA, Jan Hixon, RN, BSN, MA, Trace Hutchison, PharmD, Julia mens for the treatment of hematologic malignancies. This mono- Kirkwood, RN, BSN, Samantha Mattiucci, PharmD and Jan Schultz, graph reviews some of the salient new data recently presented at RN, MSN, CCMEP hereby state that they or their spouse/life partner international meetings of hematologists/oncologists. do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activ- Educational Objectives ity of any amount during the past 12 months. After completing this activity, the participant should be better Hazuki Aikawa: No real or apparent conflicts of interest able to: Method of Participation • Describe the importance of new study findings in the form of There are no fees for participating and receiving CME credit for this ac- selected abstracts/poster summaries in the natural history of tivity. During the period September 2009 through September 30, 2010 hematologic malignancies participants must 1) read the learning objectives and faculty disclosures; • Review the results of these new study findings including current 2) study the educational activity; 3) complete the posttest by recording clinical trials evaluating therapy in the treatment of hematologic the best answer to each question in the answer key on the evaluation malignancies form; 4) complete the evaluation form; and 5) mail or fax the evalua- • Explain how to integrate into clinical practice the latest tion form with answer key to Postgraduate Institute for Medicine. You may also complete the post-test online at www.cmeuniversity.com. On knowledge and methods for treating patients with hematologic the navigation menu, click on “Find Post-tests by Course” and search malignances in an effort to improve current prognosis by project ID 6367. Upon successfully completing the post-test and • Identify future research directions for all therapies in hematologic evaluation, your certificate will be made available immediately. malignancies A statement of credit will be issued only upon receipt of a complet- Faculty ed activity evaluation form and a completed posttest with a score of Bruce D. Cheson, MD 70% or better. Your statement of credit will be mailed to you within Elizabeth Ashforth, PhD three weeks. Accreditation Statement Media This activity has been planned and implemented in accordance Monograph with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint Disclosure of Unlabeled Use sponsorship of Postgraduate Institute for Medicine (PIM) and This educational activity may contain discussion of published and/ Millennium Medical Publishing, Inc. PIM is accredited by the or investigational uses of agents that are not indicated by the FDA. ACCME to provide continuing medical education for physicians. PIM, Millennium Medical Publishing, Inc., Celgene Corporation, and Cephalon Oncology do not recommend the use of any agent outside of Credit Designation the labeled indications. PIM designates this educational activity for a maximum of 1.5 /AMA PRA Category 1 Credit(s)TM/. Physicians should only claim credit The opinions expressed in the educational activity are those of the fac- commensurate with the extent of their participation in the activity. ulty and do not necessarily represent the views of PIM, Millennium Medical Publishing, Inc., Celgene Corporation, or Cephalon Oncol- Disclosure of Conflicts of Interest ogy. Please refer to the official prescribing information for each product PIM assesses conflict of interest with its instructors, planners, man- for discussion of approved indications, contraindications, and warnings. agers and other individuals who are in a position to control the content of continuing medical education (CME) activities. All rel- Disclaimer evant conflicts of interest that are identified are thoroughly vetted by Participants have an implied responsibility to use the newly acquired PIM for fair balance, scientific objectivity of studies utilized in this information to enhance patient outcomes and their own professional activity, and patient care recommendations. PIM is committed to development. The information presented in this activity is not meant to providing its learners with high quality CME activities and related serve as a guideline for patient management. Any procedures, medica- materials that promote improvements or quality in healthcare and tions, or other courses of diagnosis or treatment discussed or suggested not a specific proprietary business interest of a commercial interest. in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in The faculty reported the following financial relationships or use, review of any applicable manufacturer’s product information, and relationships to products or devices they or their spouse/life part- comparison with recommendations of other authorities. ner have with commercial interests related to the content of this CME activity: A Summer of Hematologic Science Highlights from the 45th Annual Meeting of the American Society of Clinical Oncology, the 14th Congress of the European Hematology Association and the 2009 Pan Pacific Lymphoma Conference he early summer of 2009 offered 3 opportuni- This abstract builds on the group’s prior observation that ties for the hematology community to come CEBPA mutations determined prior to therapy identify together and share data; the 45th Annual CN-AML patients with different outcomes, improving TMeeting of the American Society of Clinical Oncology the validity of molecular risk-based classification for this (ASCO), the 14th Congress of the European Hema- patient population.3 Taking data collected from 143 CN- tology Association (EHA), and the 2009 Pan Pacific AML patients enrolled on CALGB treatment protocols Lymphoma Conference (PPLC). These 3 meetings pro- 9621 and 19808, these authors were able to show that vided updated information on the biology, genetics, the prognostic classification of younger de novo CN- prognosis, and treatment of patients with leukemias, AML patients is improved by adding CEBPA and WT1 lymphomas, and multiple myeloma that will have a mutation and ERG expression testing. Such mutational major impact on patient management. analyses are already in place for clinical trials, access to validated testing for general use has yet to be achieved. Leukemia Becker and colleagues for the CALGB presented convinc- ing data at ASCO supporting the role of the NPM1 gene The search for valid prognostic factors in leukemia was mutation as an independent prognostic factor for older a central theme at both the ASCO and EHA meetings. patients as well.4 They compared the mutational status of Several studies demonstrated the value of genetic markers the gene with clinical outcome in 189 CN-AML patients